A Raybow USA co-authored article, “Industrial-scale chemical synthesis of gold nanorods: process optimization and 30 L scale-up toward GMP manufacturing,” was recently published in the Journal of Industrial and Engineering Chemistry.
 
David Perrey, PhD, Group Leader for Raybow USA and co-author, explained the work toward the scale-up of the production of gold nanorods.
 
“Our colleagues at the University of Bologna had a small-scale preparation and were seeking to produce nanoroads in larger quantity, having seen inconsistent results batch-to-batch in their own research. So, our challenge was to implement a more robust process, while also making the nanorods on a significantly larger scale than had been done previously.
 
“Our team was able to pinpoint the important reaction parameters to give consistent nanorod structures, as shown by the measured longitudinal LSPR.
 
“I very much enjoyed the collaboration and was very happy we were able to create a robust process to make gold nanorods for a variety of applications and research.”
 
Link to the full article here: https://www.sciencedirect.com/science/article/pii/S1226086X26000481.

Connect with Raybow USA for support with your integrated small-molecule CMC discovery, IND-enabling studies, and GMP manufacturing.
 
Molecule to Market, Raybow USA is your trusted partner!

About Raybow USA

Founded in 1998 as PharmAgra Labs by Peter Newsome and Roger Frisbee, the Brevard, North Carolina, company became Raybow USA, a US branch of JiuZhou Pharma in 2019.

The facility is dedicated to cutting-edge Research & Development and Analytical services, offering preparation of clinical trial material, method validation, and small-scale specialty manufacturing for multiple markets. The FDA-inspected site boasts a cGMP laboratory and kilo lab.

About JiuZhou Pharma

Zhejiang JiuZhou Pharmaceutical Co., LTD. (stock code: 603456.SH), founded in 1998 and headquartered in Taizhou, Zhejiang, is a leading CDMO and generic drug manufacturer in China. The company has production and R&D bases in China, Germany, Japan, and the United States.

JiuZhou Pharma provides full-lifecycle contract development and manufacturing services to pharmaceutical companies worldwide. The one-stop CDMO service spans from preclinical research, process R&D for APIs, DPs, peptides, and drug conjugates, through all clinical phases to commercial production.

###